7种新型口服抗凝药预防全髋、膝关节置换术后静脉血栓栓塞症的网状Meta分析

杨婕; 温华; 马冰; 孙晶; 杨婕; 温华; 马冰; 孙晶

doi:10.3969/j.issn.1006-0111.2018.06.014

[1]

吴丹辰,贾镭,徐希奇,等.新型口服抗凝药物预防及治疗静脉血栓栓塞症研究进展[J].中华关节外科杂志[J/OL],2013,7(3):420.

[2]

邱贵兴.中国骨科大手术静脉血栓栓塞症预防指南[J].中华关节外科杂志[J/OL],2009,3(3):380.

[3]

张超,陶华,李胜,等.应用Stata软件mvmeta程序包实现网状Meta分析[J].Chin J Evid-based Med,2014,14(9):1150-1159.

[4]

ERIKSSON B,DNHL OE,ROSENEHER N,et al.Dabigatran etexilate for prevention of venous thromboembolism after total hip replacement a randomised double-blin non-inferiority trial[J].Lancet,2007,370(9591):949-956.

[5]

ERIKSSON BI,DAHL OE,HUO MH,et al.Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty[J].Thromb Haemost,2011,105(4):721-729.

[6]

ERIKSSON B,DNHL OE,ROEENCHER N,et al.Oral dabigatran etexilate and subctltalleous enoxparin for the prevention of veneous thromboembolism after total knee replacement the RE-MODEL randomized trial[J].J Thromb Haemost,2007,5(11):2178-2185.

[7]

GINSBERG JS,DAVIDSON BL,COMP PC,et al.Oral thrombin inhibitor or dabigatan etexilate and North Ameriean enoxaparin regimen for prevention of venous thrombomembolism after knee arthroplasty surgery[J].J Arthroplasty,2009,24(1):1-9.

[8]

ERIKSSON BI,BORRIS LC,FRIEDMAN RJ,et al.Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty[J].N Engl J Med,2008,358(26):2765-2775.

[9]

KAKKAR AK,BRENNER B,DAHL OE,et al.Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty:a double-blind,randomised controlled trial[J].Lancet,2008,372(9632):31-39.

[10]

LASSEN MR,AGENO W,BORRIS LC,et al.Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty[J].N Engl J Med,2008,358(26):2776-2786.

[11]

TURPIE AG,LASSEN MR,DAVIDSON BL,et al.Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4) a randomised trial[J].Lancet,2009,373(9676):1673-1680.

[12]

ERIKSSON BI,BORRIS L,DAHL OE,et al.For the ODIXa-HIP investigators study a randomised trial:a once-daily oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939) for thromboprophylaxis after total hip replacement[J]. Circulation,2006,114(22):2374-2381.

[13]

ERIKSSON BI,BORRIS L,DAHL OE,et al.For the ODIXa-HIP investigators study a randomised trial:oral direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement[J]. Thromb Haemost,2006,4:121-128.

[14]

TURPIE, FISHER, BAUER,et al.BAY 59-7939 an oral direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement a phase Ⅱ dose-ranging study[J].Thromb Haemost,2005,3(11):2479-2486.

[15]

ERIKSSON BI,BORRIS LC,DAHL OE,et al.Dose-escalation study of rivaroxaban(BAY 59-7939) an oral direct factor Xa inhibitor-for the prevention of venous thromboembolism in patients undergoing total hip replacement[J].Thromb Res,2007,120(5):685-693.

[16]

LASSEN MR,DAVIDSON BL,GALLUS A,et al.The efficacy and safety of apixaban an oral direct factor Xa inhibitor as thromboprophylaxis in patients following total knee replacement[J].J Thromb Haemost,2007,5(12):2368-2375.

[17]

LASSEN MR,RASKOB GE,GALLUS A,et al.Apixaban or enoxaparin for thromboprophylaxis after knee replacement[J].N Engl J Med,2009,361(6):594-604.

[18]

LASSEN MR,RASKOB GE,GALLUS A,et al.Apixaban versus enoxaparin for thromboprophylaxis after knee replacement a randomised double-blind trial[J].Lancet,2010,375(9717):807-815.

[19]

LASSEN MR,GALLUS A,RASKOB GE,et al.Apixaban versus enoxaparin for thromboprophylaxis after hip replacement[J].N Engl J Med,2010,363(26):2487-2498.

[20]

FUJI T,FUJITA S,TACHIBANA S,et al.A dose-ranging study evaluating the oral factor Ⅹa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty[J].J Thromb Haemost,2010,8(11):2458-2468.

[21]

FUJI T,FUJITA S,KAWAI Y,et al.Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty:STARS J-V[J].Thromb J,2015,13:27.

[22]

RASKOB G,COHEN AT,ERIKSSON BI,et al.Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement.a randomised double-blind dose-response study[J].Thromb Haemost,2010,104(3):642-649.

[23]

TURPIE AG,BAUER KA,DAVIDSON BL,et al. A randomized evaluation of betrixaban an oral factor Xa inhibitor for prevention of thromboembolic events after total knee replacement[J].Thromb Haemost,2009,101(1):68-76.

[24]

WEITZ JI,CAO C,ERIKSSON BI,et al.A dose-finding study with TAK-442 an oral factor Xa inhibitor in patients undergoing elective total knee replacement surgery[J].Thromb Haemost,2010,104(6):1150-1157.

[25]

ERIKSSON BI,TURPIE AG,LASSEN MR,et al.Prevention of venous thromboembolism with an oral factor Xa inhibitor YM150 after total hip arthroplasty a dose finding study (ONYX-2)[J].Journal of Thrombosis and Haemostasis,2010,8:714-721.

[26]

FUJI T,NAKAMURA M,TAKEUCHI M.Darexaban for the prevention of venous thromboembolism in Asian patients undergoing orthopedic surgery results from 2 randomized placebo-controlled,double-blind studies[J].Clinical and Applied Thrombosis Hemostasis,2014,20(2):199-211.

[27]

ERIKSSON BI,AGNELLI G,GALLUS AS,et al.Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty a randomised phase Ⅱb dose confirmation study (ONYX-3)[J].Thromb Haemost,2014,111(2):213-225.

[28]

STEVENSON M,SCOPE A,HOLMES M,et al.Rivaroxaban for the prevention of venous thromboembolism a single technology appraisal[J].Health Technol Assess,2009,13:43-48.

[29]

GOMEZ-OUTESA,TERLEIRA-FERNANDEZ AI,SUAREZ-GEA ML,et al.Dabigatran rivaroxaban or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement systematic review meta-analysis,and indirect treatment comparisons[J].BMJ,2012,344(14):3675.